Hepatic hydrothorax - Pathophysiology, diagnosis, and management
Hepatic hydrothorax - Pathophysiology, diagnosis, and management
复制标题
DOI：
10.1097/00004836-200401000-00012
复制
发表时间：
2004-01-01
影响因子：
2.9
通讯作者：
Mihas, AA
中科院分区：
文献类型：
--
作者：
Garcia, N;Mihas, AA
肝性胸水发生在大约5%到12%的肝硬化和门静脉高压症患者中。从饮食和药物干预到手术方法的各种治疗方式可用于这种情况的管理。治疗必须根据患者对保守治疗的反应以及基础肝病的严重程度进行个体化。肝性胸水可并发自发性细菌性脓胸，预后差，死亡率可达20%。所有肝性胸水患者均应评估肝移植的可能性。
Hepatic hydrothorax occurs in approximately 5 to 12% of patients with cirrhosis and portal hypertension. Various therapeutic modalities ranging from dietary and pharmacologic interventions to surgical approaches are available for the management of this condition. Treatment must be individualized based on the patient's response to conservative management as well as the severity of the underlying liver disease. Hepatic hydrothorax may be complicated by spontaneous bacterial empyema, which portends a poor prognosis with a mortality rate of up to 20%. All patients with hepatic hydrothorax should be evaluated for possible liver transplantation.